Page last updated: 2024-08-24

relcovaptan and Androgen-Independent Prostatic Cancer

relcovaptan has been researched along with Androgen-Independent Prostatic Cancer in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Burnstein, KL; Copello, VA; Daaka, Y; Fahrenholtz, CD; Greene, AM; Heidman, LM; Lo, CH; Lynch, CC; Magani, F; Martinez, MJ; Peacock, SO; Rice, MA; Zhang, Y; Zhao, N	1

Other Studies

1 other study(ies) available for relcovaptan and Androgen-Independent Prostatic Cancer

Article	Year
Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer. Science translational medicine, 2019, 06-26, Volume: 11, Issue:498 Topics: Animals; Calcium; Cell Line, Tumor; Cell Proliferation; Cyclic AMP Response Element-Binding Protein; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Indoles; Male; MAP Kinase Signaling System; Mice, Nude; Molecular Targeted Therapy; Osteogenesis; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-vav; Pyrrolidines; Receptors, Androgen; Receptors, Vasopressin; RNA, Messenger	2019

Article

Year

Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer.

Science translational medicine, 2019, 06-26, Volume: 11, Issue:498

Topics: Animals; Calcium; Cell Line, Tumor; Cell Proliferation; Cyclic AMP Response Element-Binding Protein; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Indoles; Male; MAP Kinase Signaling System; Mice, Nude; Molecular Targeted Therapy; Osteogenesis; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-vav; Pyrrolidines; Receptors, Androgen; Receptors, Vasopressin; RNA, Messenger

2019